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Cutaneous
Clopidogrel Hypersensitivity
Give Steroids and
Do Not Stop the Clopidogrel*
Paul A. Gurbel, MD,
Young-Hoon Jeong, MD, PHD,
Udaya S. Tantry, PHD
Baltimore, Maryland
Dual antiplatelet therapy (DAPT) with clopidogrel and
aspirin is widely used as a secondary prevention strategy in
patients with acute coronary syndrome and following stent
implantation. Ideally, at least 1 year of uninterrupted DAPT
is recommended for patients with acute coronary syndrome
and for patients treated with drug-eluting stents (1,2). In
this issue of the Journal, the work of Cheema et al. (3)
highlights a difficult clinical problem associated with clopi-
dogrel therapy—cutaneous hypersensitivity. Attending
physicians are all aware of the major concern of jeopardizing
patient safety by early discontinuation of therapy to alleviate
See page 1445
the troublesome skin rash symptoms. Discontinuation of
either aspirin or clopidogrel, particularly early after stent
implantation, is associated with a heightened risk of stent
thrombosis (4). Unfortunately, cutaneous hypersensitivity
most often begins within 5 to 6 days of the initiation of
DAPT (5). Moreover, there are no definitive guidelines
instructing the clinician on the proper management of this
side effect. Often antihistamines and/or a course of steroids
will be administered in an attempt to carry on with the
current antiplatelet regimen (5). Concomitant therapies
associated with potential hypersensitivity may be selectively
discontinued. If these measures fail, the physician is con-
fronted with the decision to switch thienopyridine therapy
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this strategy. Thus far, no standardized assays are available
to confirm clopidogrel-related allergic reactions. In light of
our limitation of not knowing the optimal method to
diagnose and treat the patient with a rash on clopidogrel
therapy, the contribution of Cheema et al. (3) is welcomed.
To the best of our knowledge, this report is the single most
comprehensive assessment of the mechanisms underlying
clopidogrel hypersensitivity and its treatment. The data of
Cheema et al. (3) provide the clinician with reassurance that
a simple treatment is safe and highly effective and that
interruption of clopidogrel therapy is not required.
Clopidogrel therapy has been increasing, and it accounted
for approximately $10 billion in worldwide sales in 2009 (6).
oreover, the patent for clopidogrel will soon expire in the
nited States, and usage will likely remain high with less
xpensive generic agents on the horizon. Therefore, even a low
verall prevalence of hypersensitivity reactions will affect the
linical impact in a substantial number of patients. There are
umerous publications describing desensitization protocols for
lopidogrel hypersensitivity that are similar to those employed
or aspirin allergy (5,7,8). The latter protocols have included
ntensive care unit observation periods and multiday outpatient
egimens; a 90% success rate has been reported. However, these
rotocols require a drug washout period, which is undesirable
articularly early after stenting, when the rash arises (8).
Cheema et al. (3) evaluated 62 patients who underwent
ercutaneous revascularization at a single medical center
nd developed a probable or definite hypersensitivity reac-
ion attributable to clopidogrel therapy. The prevalence of
he reaction was 62 in 3,877 (1.6%). These patients were
reated with a 3-week tapering course of prednisone begin-
ing with 30 mg twice daily; they also received diphenhy-
ramine 25 to 50 mg every 6 to 8 h as needed. The latter
trategy was successful in 95% of patients; rash resolved at a
edian of 5  2 days, and clopidogrel therapy did not have
o be interrupted in a single patient. Only 1 patient with
ngioedema required hospitalization (3).
It is important to note that the paper by Cheema et al. (3)
nly addressed cutaneous reactions. Other clinical manifesta-
ions of hypersensitivity to clopidogrel include fever, abdominal
ain, neutropenia, and thrombocytopenia. Very rarely throm-
otic thrombocytopenia purpura (4 cases per million patients)
as also been associated with clopidogrel therapy (9). In a study
y Lokhandwala et al. (10) of 76 patients with a hypersensi-
ivity reaction to clopidogrel, 93% had a rash, 5% had angio-
dema, 4% had thrombocytopenia, and 3% had neutropenia.
n another report of 24 cases of clopidogrel allergy, the most
ommon presentation was a pruritic, erythematous, macular,
nd confluent rash that began on the face or trunk and spread
o the extremities (7). In the CAPRIE (Clopidogrel versus
spirin in Patients at Risk of Ischaemic Events) trial, approx-
mately 6% of patients suffered from a pruritic rash, which
ccounted for 1.5% of clopidogrel discontinuation (11). In the
RITON–TIMI 38 (Trial to Assess Improvement in Thera-
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Prasugrel–Thrombolysis in Myocardial Infarction 38) study,
approximately 4% of patients treated with clopidogrel or
prasugrel suffered allergic reactions, such as anaphylactic reac-
tion, rash, pruritus, and urticaria (12). Notably, the prevalence
of hypersensitivity to clopidogrel in the Cheema et al. study (3)
was lower and may reflect underreporting. In the PLATO
(Platelet Inhibition and Patient Outcomes) trial, clopidogrel
and ticagrelor treatments were associated with a 1.7% and 1.6%
prevalence of allergy and hypersensitivity, respectively (13).
In the study by Cheema et al. (3), generalized exanthema
occurred in 79%, localized skin reaction in 16%, and angioedema
or urticaria in 5% of patients. The rash findings observed by
Cheema et al. (3) and the timing of onset are largely consistent
with prior reports (5,7). Recently, in a review of medical records,
Campbell et al. (14) reported the resolution of hypersensitivity
symptoms without interrupting clopidogrel therapy among 25
patients treated with stenting (64% drug-eluting stents). In the
Campbell et al. study (14), drug sensitivity was observed 6  2
days after clopidogrel initiation. The patients were treated with
corticosteroids and antihistamines (corticosteroids or antihista-
mines in 5 patients each and both drugs in 15 patients) for amean
of 10  8 days, and clopidogrel therapy was continued without
interruption. The latter therapy was effective in 22 of 25 patients
(88%), and there were no incidences of adverse clinical events in
the long-term follow-up of up to 1,138 days (14).
The study byCheema et al. (3) stands out fromprevious studies
in many aspects. In addition to evaluating therapy, the investiga-
tors performed hematologic measurements, skin testing, and
histological analyses to elucidate the mechanism of clopidogrel
hypersensitivity; they also assessed cross-reactivity with other
thienopyridines. The results of skin prick and intradermal testing
was rarely positive. However, patch testing was frequently abnor-
mal (81%). These latter findings, in combination with the timing
of rash onset and histological analysis of punch biopsies performed
in a minority of patients, point to a lymphocyte-mediated delayed
hypersensitivity reaction (type IV) as the responsible mechanism
in the majority of patients; only 7% of patients had immediate
hypersensitivity reactions with angioedema or urticaria. In addi-
tion, the investigators performed cross-reactivity testing and found
a significant rate of positive reactions: 24% to ticlopidine, 17% to
prasugrel, and 7% to both ticlopidine and prasugrel (3). The latter
observations indicated that switching to other thienopyridines
may not necessarily be an effective remedy to overcome clopidogrel
hypersensitivity. Clinical experience is less frequent with prasug-
rel—as compared with clopidogrel-treated patients—and the
prevalence of hypersensitivity is less certain. Recently, based on
case reports, the European Medicines Agency requested that
Daiichi Sankyo Inc. and Eli Lilly inform physicians of the
potential risk of hypersensitivity reactions to prasugrel (15). The
use of a nonthienopyridine P2Y12 inhibitor such as ticagrelor may
e particularly effective in a patient with clopidogrel hypersensi-
ivity. However, the study by Cheema et al. (3) strongly suggests
hat treatment with a course of prednisone is a safe, moderately
apid, and highly effective strategy for patients suffering fromutaneous clopidogrel hypersensitivity. DAPT can continue with-
ut interruption, and no switching is necessary. This is very good
ews for the troubled patient and worried physician.
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